Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.64 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.52 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.52 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.52 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.52 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.52 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.52 |
| ▸ | CDK2 | P24941 | 7/20 | 0.50 |
| ▸ | CDK4 | P11802 | 6/20 | 0.50 |
| ▸ | CDK1 | P06493 | 5/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.50 |
| ▸ | CCND1 | P24385 | 5/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 9/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 9/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 9/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057399 | 0.82 | ADORA2A (0.65) | ADORA2AADORA2BADORA1CDK2CDK4 | |
| SCHEMBL4050026 | 0.78 | ADORA2B (0.59) | ADORA2AADORA2BADORA1PRKAB2PRKAG1 | |
| SCHEMBL4048696 | 0.78 | ADORA2B (1.00) | ADORA2AADORA2BADORA1 | |
| SCHEMBL21621270 | 0.78 | PRKAA1 (0.49) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4051221 | 0.78 | ADORA2B (0.67) | ADORA2AADORA2BADORA1 | |
| SCHEMBL4054613 | 0.78 | ADORA2B (0.67) | ADORA2AADORA2BADORA1CDK2CCNA2 | |
| SCHEMBL4056111 | 0.76 | ADORA2B (0.65) | ADORA2AADORA2BADORA1 | |
| SCHEMBL4056139 | 0.76 | ADORA2B (0.65) | ADORA2AADORA2BADORA1 | |
| SCHEMBL4052502 | 0.75 | ADORA2B (0.64) | ADORA2AADORA2BADORA1 | |
| SCHEMBL21621269 | 0.69 | PRKAB2 (0.60) | ADORA2AADORA2BADORA1PRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1942469-B | Condensed pyridine derivatives useful as A28 adenosine receptor antagonists | ALMIRALL LAB | 2010-07-07 | — | — | CN | claimed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | claimed |
| CN-1942469-A | Condensed pyridine derivatives useful as A28 adenosine receptor antagonists | ALMIRALL LAB (ES) | 2007-04-04 | — | — | CN | claimed |
| CN-1942469-B | Condensed pyridine derivatives useful as A28 adenosine receptor antagonists | ALMIRALL LAB | 2010-07-07 | — | — | CN | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| CN-1942469-A | Condensed pyridine derivatives useful as A28 adenosine receptor antagonists | ALMIRALL LAB (ES) | 2007-04-04 | — | — | CN | disclosed |
| EP-1735310-A1 | CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005100353-A1 | CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL PRODESFARMA, SA (ES) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA2B 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.